Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-Leiden mice

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 1, 2005, Pages 53-60

  Delsing, Dianne J M ^a   Post, Sabine M ^a   Groenendijk, Martine ^a   Solaas, Karianne ^a   Van Der Boom, Hans ^a   Van Duyvenvoorde, Wim ^a   De Wit, Elly C M ^a   Bloks, Vincent W ^b   Kuipers, Folkert ^b   Havekes, Louis M ^a   Princen, Hans M G ^a  

^a TNO   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Cholesterol; Gene expression; Lipid metabolism; Lipoproteins; Statin

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E3; BILE ACID; DIACYLGLYCEROL ACYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PHOSPHOLIPID; ROSUVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HEPATOBILIARY SYSTEM; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID DIET; LIPID LIVER LEVEL; LIPOLYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEINS B; APOLIPOPROTEINS E; BILE; BILE ACIDS AND SALTS; CHOLESTEROL; CHOLESTEROL, VLDL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; FEMALE; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MICE; MICE, TRANSGENIC; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEROLS; SULFONAMIDES; TRIGLYCERIDES;

EID: 19944407536     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200501000-00010     Document Type: Article

References (40)

1. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol. 1999;19:187-195.
2. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
3. Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res. 1996;37:439-447.
4. Burnett JR, Wilcox LJ, Telford DE, et al. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Arterioscler Thromb Vasc Biol. 1997;17: 2589-2600.
5. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81:66B-69B.
6. Verd JC, Peris C, Alegret M, et al. Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. Br J Pharmacol. 1999;127:1479-1485.
7. Schoonjans K, Peinado-Onsurbe J, Fruchart JC, et al. 3-Hydroxy-3- methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 1999;452:160-164.
8. Krause BR, Princen HM. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis. 1998;140:15-24.
9. Bisgaier CL, Essenburg AD, Auerbach BJ, et al. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J Lipid Res. 1997;38:2502-2515.
10. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has antiinflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001;21:115-121.
11. Quarfordt SH, Oswald B, Landis B, et al. In vivo cholesterol kinetics in apolipoprotein E-deficient and control mice. J Lipid Res. 1995;36:1227-1235.
12. van den Maagdenberg AM, Hofker MH, Krimpenfort PJ, et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem. 1993;268:10540-10545.
13. Volger OL, van der Boom H, de Wit EC, et al. Dietary plant stanol esters reduce VLDL cholesterol secretion and bile saturation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol. 2001;21: 1046-1052.
14. Delsing DJ, Offerman EH, van Duyvenvoorde W, et al. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation. 2001;103:1778-1786.
15. Princen HM, Kleemann R, Verschuren L, et al. The PPAR-α-agonist fenofibrate reduces development of atherosclerosis beyond and independently of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice. Atherosclerosis. 2003;4:164.
16. van Vlijmen BJ, Pearce NJ, Bergo M, et al. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs. Arzneimittelforschung. 1998;48:396-402.
17. Delsing DJ, Jukema JW, van de Wiel MA, et al. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J Cardiovasc Pharmacol. 2003;42:63-70.
18. van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest. 1994;93:1403-1410.
19. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Polin phenol reagent. J Biol Chem. 1951;193:265-275.
20. Havekes LM, de Wit EC, Princen HM. Cellular free cholesterol in Hep G2 cells is only partially available for down-regulation of low-density-lipoprotein receptor activity. Biochem J. 1987;247:739-746.
21. Post SM, de Roos B, Vermeulen M, et al. Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis. Arterioscler Thromb Vasc Biol. 2000; 20:1551-1556.
22. Bloks VW, Plosch T, van Goor H, et al. Hyperlipidemia and atherosclerosis associated with liver disease in ferrochelatase-deficient mice. J Lipid Res. 2001;42:41-50.
23. Post SM, de Crom R, van Haperen R, et al. Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein. Arterioscler Thromb Vasc Biol. 2003;23:892-897.
24. Kuipers F, van Ree JM, Hofker MH, et al. Altered lipid metabolism in apolipoprotein E-deficient mice does not affect cholesterol balance across the liver. Hepatology. 1996;24:241-247.
25. Post SM, Zoeteweij JP, Bos MH, et al. Acyl-coenzyme A:cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7alpha-hydroxylase in cultured rat hepatocytes and in vivo in the rat. Hepatology. 1999;30:491-500.
26. Post SM, Groenendijk M, Solaas K, et al. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production. Arterioscler Thromb Vasc Biol. 2004;24: 768-774.
27. Bey L, Maigret P, Laouenan H, et al. Induction of lipoprotein lipase gene expression in 3T3-L1 preadipocytes by atorvastatin, a cholesterol- and triglyceride-lowering drug. Pharmacology. 2002;66:51-56.
28. Horton JD, Shimomura I, Brown MS, et al. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest. 1998;101:2331-2339.
29. Shimano H, Yahagi N, Amemiya-Kudo M, et al. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem. 1999;274:35832-35839.
30. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87:28B-32B.
31. Aguilar-Salinas CA, Barrett H, Schonfeld G. Metabolic modes of action of the statins in the hyperlipoproteinemias. Atherosclerosis. 1998;141: 203-207.
32. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34:1637-1659.
33. Horton JD, Cuthbert JA, Spady DK. Regulation of hepatic 7 alpha-hydroxylase expression and response to dietary cholesterol in the rat and hamster. J Biol Chem. 1995;270:5381-5387.
34. Shimomura I, Bashmakov Y, Shimano H, et al. Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver. Proc Natl Acad Sci USA. 1997;94:12354-12359.
35. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
36. Ginsberg HN. Effects of statins on triglyceride metabolism. Am J Cardiol. 1998;81:32B-35B.
37. Waterman IJ, Zammit VA. Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities. Diabetes. 2002;51:1708-1713.
38. Sato R, Miyamoto W, Inoue J, et al. Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription. J Biol Chem. 1999;274:24714-24720.
39. Wilcox LJ, Barrett PH, Huff MW. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999;40:1078-1089.
40. Hanson DS, Duane WC. Effects of lovastatin and chenodiol on bile acid synthesis, bile lipid composition, and biliary lipid secretion in healthy human subjects. J Lipid Res. 1994;35:1462-1468.